GSK To Hand Over $227M For Basilea Eczema Drug

Law360, New York (June 12, 2012, 2:24 PM EDT) -- A GlaxoSmithKline PLC unit will get patent, trademark and distribution rights for a popular eczema drug, beefing up its skin care business in exchange for an initial payment of £146 million ($227 million) to Swiss biotech firm Basilea Pharmaceutica Ltd., the companies said Monday.

The Swiss company could see an additional payment of up to £50 million if Toctino is greenlit by the U.S. Food and Drug Administration for use in the U.S., where it is in its third phase of trials, GSK subsidiary Stiefel Laboratories...
To view the full article, register now.